The opioidergic system: Potential roles and therapeutic indications in the eye (invited review)

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 2, 2008, Pages 117-140

  Husain, Shahid ^a   Potter, David E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; DELTA OPIATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; ION CHANNEL; KAPPA OPIATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MU OPIATE RECEPTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OPIATE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN KINASE C;

APOPTOSIS; AQUEOUS HUMOR FLOW; BINDING SITE; CELL PROLIFERATION; CELL SURVIVAL; DIMERIZATION; DYNAMICS; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; IRIS; LACRIMAL GLAND; MIOSIS; MYDRIASIS; NEUROPROTECTION; NONHUMAN; PROTEIN FUNCTION; RETINA; RETINOPATHY; REVIEW; WOUND HEALING;

ANALGESICS, OPIOID; ANIMALS; EYE; EYE DISEASES; HUMANS; LIGANDS; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION;

EID: 41449118507     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0112     Document Type: Review

References (288)

1. Gutstein, H.B., and Akil, H. Opioid analgesics. In: Hardman, J.G., and Limbird, L.E., eds. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001:569-619.
2. Martin, W.R. Opioid antagonists. Pharmacol. Rev. 19:463-521, 1967.
3. Pert, C.B., and Snyder, S.H. Opiate receptor: demonstration in nervous tissue. Science 179:1011-1014, 1973.
4. Norn, S., Kruse, P.R., and Kruse, E. [History of opium poppy and morphine]. Dan. Medicinhist Arbog. 33:171-184, 2005.
5. Gross, E.R., and Gross, G.J. Ligand triggers of classical preconditioning and postconditioning. Cardiovasc. Res. 70:212-221, 2006.
6. Kuzume, K., Wolff, R.A., Amakawa, K., et al. Sustained exogenous administration of Met5-enkephalin protects against infarction in vivo. Am. J. Physiol. Heart Circ. Physiol. 285:H2463-H2470, 2003.
7. Rogers, T.J., and Peterson, P.K. Opioid G-protein-coupled receptors: Signals at the crossroads of inflammation. Trends Immunol. 24:116-121, 2003.
8. Leopold, I.H., and Comroe, J.H. Effect of intramuscular administration of morphine, atropine, scopolamine, and neostigmine on the human eye. Arch. Ophthalmol. 36:285-290, 1946.
9. Drago, F., Aguglia, E., Dal Bello, A., et al. Ocular instillation of naloxone increases intraocular pressure in morphine-addicted patients: A possible test for detecting misuse of morphine. Experientia 41:266-267, 1985.
10. Wang, D., and Potter, D.E. Ocular action of an opioid peptide, DPDPE. J. Ocul. Pharmacol. Ther. 12:131-139, 1996.
11. Russell, K.R., Wang, D.R., and Potter, D.E. Modulation of ocular hydrodynamics and iris function by bremazocine, a kappa opioid receptor agonist. Exp. Eye Res. 70:675-682, 2000.
12. Russell, K.R., and Potter, D.E. Dynorphin modulates ocular hydrodynamics and releases atrial natriuretic peptide via activation of kappa-Opioid receptors. Exp. Eye Res. 75:259-270, 2002.
13. Zagon, I.S., Sassani, J.W., and McLaughlin, P.J. Reepithelialization of the human cornea is regulated by endogenous opioids. Invest. Ophthalmol. Vis. Sci. 41:73-81, 2000.
14. 3H-NE release and cAMP accumulation. Exp. Eye Res. 73:167-178, 2001.
15. Stiles, J., Honda, C.N., Krohne, S.G., et al. Effect of topical administration of 1% morphine sulfate solution on signs of pain and corneal wound healing in dogs. Am. J. Vet. Res. 64:813-818, 2003.
16. Isayama, T., Hurst, W.J., McLaughlin, P.J., et al. Ontogeny of the opioid growth factor, [Met5]-enkephalin, and its binding activity in the rat retina. Vis. Neurosci. 12:939-950, 1995.
17. Isayama, T., McLaughlin, P.J., and Zagon, I.S. Ontogeny of preproenkephalin mRNA expression in the rat retina. Vis. Neurosci. 13:695-704, 1996.
18. Isayama, T., McLaughlin, P.J., and Zagon, I.S. Endogenous opioids regulate cell proliferation in the retina of developing rat. Brain Res. 544:79-85, 1991.
19. Drago, F., Panissidi, G., Bellomio, F., et al. Effects of opiates and opioids on intraocular pressure of rabbits and humans. Clin. Exp. Pharmacol. Physiol. 12:107-113, 1985.
20. Drago, F., Gorgone, G., Spina, F., et al. Opiate receptors in the rabbit iris. Naunyn Schmiedeberg's Arch. Pharmacol. 315:1-4, 1980.
21. Selbach, J.M., Buschnack, S.H., Steuhl, K.P., et al. Substance P and opioid peptidergic innervation of the anterior eye segment of the rat: An immunohistochemical study. J. Anat. 206:237-242, 2005.
22. Stone, R.A., Kuwayama, Y., and Laties, A.M. Regulatory peptides in the eye. Experientia 43:791-800, 1987.
23. Wamsley, J.K., Palacios, J.M., and Kuhar, M.J. Autoradiographic localization of opioid receptors in the mammalian retina. Neurosci. Lett. 27:19-24, 1981.
24. Beckett, A.H., and Casy, A.F. Synthetic analgesics: Stereochemical considerations. J. Pharm. Pharmacol. 6:986-1001, 1954.
25. Portoghese, P.S. A new concept on the mode of interaction of narcotic analgesics with receptors. J. Med. Chem. 8:609-616, 1965.
26. Terenius, L. Stereospecific interaction between narcotic analgesics and a synaptic plasm a membrane fraction of rat cerebral cortex. Acta. Pharmacol. Toxicol. (Copenh.) 32:317-320, 1973.
27. 3H) Etorphine to rat-brain homogenate. Proc. Natl. Acad. Sci. U.S.A. 70:1947-1949, 1973.
28. Meunier, J.C., Mollereau, C., Toll, L., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532-535, 1995.
29. Reinscheid, R.K., Nothacker, H.P., Bourson, A., et al. Orphanin FQ: A neuropeptide that activates an opioidlike G-protein-coupled receptor. Science 270:792-794, 1995.
30. Fichna, J., Gach, K., Piestrzeniewicz, M., et al. Functional characterization of opioid receptor ligands by aequorin luminescence-based calcium assay. J. Pharmacol. Exp. Ther. 317:1150-1154, 2006.
31. Kieffer, B.L., Befort, K., Gaveriaux-Ruff, C., et al. The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U.S.A. 89:12048-12052, 1992.
32. Evans, C.J., Keith, D.E., Jr., Morrison, H., et al. Cloning of a delta opioid receptor by functional expression. Science 258:1952-1955, 1992.
33. Fukuda, K., Kato, S., Mori, K., et al. Primary structures and expression from cDNAs of rat opioid receptor delta- and mu-subtypes. FEBS Lett. 327:311-314, 1993.
34. Knapp, R.J., Malatynska, E., Fang, L., et al. Identification of a human delta opioid receptor: Cloning and expression. Life Sci. 54:PL463-PL469, 1994.
35. Zhu, Y., Hsu, M.S., and Pintar, J.E. Developmental expression of the mu, kappa, and delta opioid receptor mRNAs in mouse. J. Neurosci. 18:2538-2549, 1998.
36. Wittert, G., Hope, P., and Pyle, D. Tissue distribution of opioid receptor gene expression in the rat. Biochem. Biophys. Res. Commun. 218:877-881, 1996.
37. Vanderah, T., Takemori, A.E., Sultana, M., et al. Interaction of [D-Pen2,D-Pen5]enkephalin and [D-Ala2, Glu4]deltorphin with delta-opioid receptor subtypes in vivo. Eur. J. Pharmacol. 252:133-137, 1994.
38. Jiang, Q., Takemori, A.E., Sultana, M., et al. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5′-isothiocyanate: Evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. 257:1069-1075, 1991.
39. Varga, E.V., Stropova, D., Kim, T., et al. Coupling of human delta-opioid receptor to retinal rod transducin in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 292:209-214, 2000.
40. Dortch-Carnes, J., and Potter, D.E. Delta-opioid agonist-stimulated inositol phosphate formation in isolated, rabbit iris-ciliary bodies: Role of G(i/o) proteins and Gbetagamma-subunits. Exp. Eye Res. 77:647-652, 2003.
41. Meneray, M.A., Fields, T.Y., and Bennett, D.J. Gi/Go couple met-enkephalin to inhibition of cholinergic and beta-adrenergic stimulation of lacrimal secretion. Cornea 19:92-98, 2000.
42. Meng, F., Xie, G.X., Thompson, R.C., et al. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc. Natl. Acad. Sci. U.S.A. 90:9954-9958, 1993.
43. Yasuda, K., Raynor, K., Kong, H., et al. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc. Natl. Acad. Sci. U.S.A. 90:6736-6740, 1993.
44. Simonin, F., Gaveriaux-Ruff, C., Befort, K., et al. kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 92:7006-7010, 1995.
45. Xie, G.X., Meng, F., Mansour, A., et al. Primary structure and functional expression of a guinea pig kappa opioid (dynorphin) receptor. Proc. Natl. Acad. Sci. U.S.A. 91:3779-3783, 1994.
46. Akil, H., and Watson, S.J. Cloning of kappa opioid receptors: Functional significance and future directions. Prog. Brain Res. 100:81-86, 1994.
47. Chen, Y., Mestek, A., Liu, J., et al. Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol. Pharmacol. 44:8-12, 1993.
48. Min, B.H., Augustin, L.B., Felsheim, R.F., et al. Genomic structure analysis of promoter sequence of a mouse mu-opioid receptor gene. Proc. Natl. Acad. Sci. U.S.A. 91:9081-9085, 1994.
49. Wang, J.B., Johnson, P.S., Persico, A.M., et al. Human mu-opiate receptor. cDNA and genomic clones, pharmacologic characterization, and chromosomal assignment. FEBS Lett. 338:217-222, 1994.
50. Pampusch, M.S., Osinski, M.A., Brown, D.R., et al. The porcine mu-opioid receptor: Molecular cloning and mRNA distribution in lymphoid tissues. J. Neuroimmunol. 90:192-198, 1998.
51. Onoprishvili, I., Andria, M.L., Vilim, F.S., et al. The bovine mu-opioid receptor: Cloning of cDNA and pharmacological characterization of the receptor expressed in mammalian cells. Brain Res. Mol. Brain Res. 73:129-137, 1999.
52. Barrallo, A., Gonzalez-Sarmiento, R., Alvar, F., et al. ZFOR2, a new opioid receptor-like gene from the teleost zebrafish (Danio rerio). Brain Res. Mol. Brain Res. 84:1-6, 2000.
53. Reisine, T., and Bell, G.I. Molecular biology of opioid receptors. Trends Neurosci. 16:506-510, 1993.
54. Dortch-Carnes, J., and Russell, K.R. Morphine-induced reduction of intraocular pressure and pupil diameter: Role of nitric oxide. Pharmacology 77:17-24, 2006.
55. Martin, W.R., Eades, C.G., Thompson, J.A., et al. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197:517-532, 1976.
56. Hanner, M., Moebius, F.F., Flandorfer, A., et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc. Natl. Acad. Sci. U.S.A. 93:8072-8077, 1996.
57. Monassier, L., and Bousquet, P. Sigma receptors: From discovery to highlights of their implications in the cardiovascular system. Fund. Clin. Pharmacol. 16:1-8, 2002.
58. Schoenwald, R.D., Barfknecht, C.F., Shirolkar, S., et al. Identification of sigma receptors in lacrimocytes and their therapeutic implications in dry eye syndrome. Adv. Exp. Med. Biol. 350:141-146, 1994.
59. Wang, L., Prescott, A.R., Spruce, B.A., et al. Sigma receptor antagonists inhibit lens cell growth and induce pigmentation. Invest. Ophthalmol. Vis. Sci. 46:1403-1408, 2005.
60. Bucolo, C., Campana, G., DiToro, R., et al. Sigma-1 recognition in rabbit iris-ciliary body: Topical sigma-1 site agonists lower intraocular pressure. J. Pharmacol. Exp. Ther. 289:1362-1369, 1999.
61. Senda, T., Matsino, K., and Mita, S. The presence of sigma receptor subtypes in bovine retinal membranes. Exp. Eye Res. 64:857-860, 1997.
62. Zagon, I.S., Verderame, M.F., Allen, S.S., et al. Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans. Brain Res. 856:75-83, 2000.
63. Trujillo, K.A., and Akil, H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251:85-87, 1991.
64. Watkins, L.R., Kinscheck, I.B., and Mayer, D.J. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 224:395-396, 1984.
65. Roques, B.P., and Noble, F. Association of enkephalin catabolism inhibitors and CCK-B antagonists: A potential use in the management of pain and opioid addiction. Neurochem. Res. 21:1397-1410, 1996.
66. Menard, D.P., van Rossum, D., Kar, S., et al. A calcitonin gene-related peptide receptor antagonist prevents the development of tolerance to spinal morphine analgesia. J. Neurosci. 16:2342-2351, 1996.
67. Parolaro, D., Patrini, G., Giagnoni, G., et al. Pertussis toxin inhibits morphine analgesia and prevents opiate dependence. Pharmacol. Biochem. Behav. 35:137-141, 1990.
68. Gomes, B.A., Shen, J., Stafford, K., et al. Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling. Pharmacol. Biochem. Behav. 72:273-278, 2002.
69. Law, P.Y., Louie, A.K., and Loh, H.H. Effect of pertussis toxin treatment on the down-regulation of opiate receptors in neuroblastoma X glioma NG108-15 hybrid cells. J. Biol. Chem. 260:14818-14823, 1985.
70. Liang, D.Y., Shi, X., Li, X., et al. The beta-2 adrenergic receptor regulates morphine tolerance and physical dependence. Behav. Brain Res. 181:118-126, 2007.
71. Petraschka, M., Li, S., Gilbert, T.L., et al. The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu-opioid receptors following partial sciatic nerve ligation. Neuroscience 146:1795-1807, 2007.
72. Marie, N., Landemore, G., Debout, C., et al. Pharmacological characterization of AR-M1000390 at human delta opioid receptors. Life Sci. 73:1691-1704, 2003.
73. Marie, N., Lecoq, I., Jauzac, P., et al. Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists. J. Biol. Chem. 278:22795-22804, 2003.
74. Allouche, S., Polastron, J., Hasbi, A., et al. Differential G-protein activation by alkaloid and peptide opioid agonists in the human neuroblastoma cell line SK-N-BE. Biochem. J. 342(Pt. 1):71-78, 1999.
75. Lecoq, I., Marie, N., Jauzac, P., et al. Different regulation of human delta-opioid receptors by SNC-80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5- dimethyl-1-piperazinyl)-3-meth oxybenzyl]-N,N-diethylbenzamide] and endogenous enkephalins. J. Pharmacol. Exp. Ther. 310:666-677, 2004.
76. Koch, T., Schulz, S., Schroder, H., et al. Carboxyl-terminal splicing of the rat mu-opioid receptor modulates agonist-mediated internalization and receptor resensitization. J. Biol. Chem. 273:13652-13657, 1998.
77. Prather, P.L., Tsai, A.W., and Law, P.Y. Mu- and delta-opioid receptor desensitization in undifferentiated human neuroblastoma SHSY5Y cells. J. Pharmacol. Exp. Ther. 270:177-184, 1994.
78. Malatynska, E., Wang, Y., Knapp, R.J., et al. Human delta-opioid receptor: Functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80. J. Pharmacol. Exp. Ther. 278:1083-1089, 1996.
79. Yoburn, B.C., Gomes, B.A., Rajashekara, V., et al. Role of G(i)alpha-2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo. Synapse 47:109-116, 2003.
80. Belcheva, M.M., Barg, J., McHale, R.J., et al. Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine. Mol. Pharmacol. 44:173-179, 1993.
81. Patel, M.B., Patel, C.N., Rajashekara, V., et al. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo. Mol. Pharmacol. 62:1464-1470, 2002.
82. Polastron, J., Meunier, J.C., and Jauzac, P. Chronic morphine induces tolerance and desensitization of mu-opioid receptor but not down-regulation in rabbit. Eur. J. Pharmacol. 266:139-146, 1994.
83. Shen, J., Benedict Gomes, A., Gallagher, A., et al. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice. Synapse 38:322-327, 2000.
84. Raynor, K., Kong, H., Hines, J., et al. Molecular mechanisms of agonist-induced desensitization of the cloned mouse kappa opioid receptor. J. Pharmacol. Exp. Ther. 270:1381-1386, 1994.
85. Zhu, J., Luo, L.Y., Mao, G.F., et al. Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 285:28-36, 1998.
86. Pak, Y., Kouvelas, A., Scheideler, M.A., et al. Agonist-induced functional desensitization of the muopioid receptor is mediated by loss of membrane receptors rather than uncoupling from G-protein. Mol. Pharmacol. 50:1214-1222, 1996.
87. Garzon, J., Rodriguez-Diaz, M., Lopez-Fando, A., et al. RGS9 proteins facilitate acute tolerance to muopioid effects. Eur. J. Neurosci. 13:801-811, 2001.
88. Garzon, J., Rodriguez-Munoz, M., Lopez-Fando, A., et al. RGSZ1 and GAIP regulate mu- but not delta-opioid receptors in mouse CNS: Role in tachyphylaxis and acute tolerance. Neuropsychopharmacology 29:1091-1104, 2004.
89. Garzon, J., Rodriguez-Diaz, M., Lopez-Fando, A., et al. Glycosylated phosducin-like protein long regulates opioid receptor function in mouse brain. Neuropharmacology 42:813-828, 2002.
90. Whistler, J.L., Chuang, H.H., Chu, P., et al. Functional dissociation of mu-opioid receptor signaling and endocytosis: Implications for the biology of opiate tolerance and addiction. Neuron 23:737-746, 1999.
91. Finn, A.K., and Whistler, J.L. Endocytosis of the mu-opioid receptor reduces tolerance and a cellular hall-mark of opiate withdrawal. Neuron 32:829-839, 2001.
92. Claing, A., Laporte, S.A., Caron, M.G., et al. Endocytosis of G-protein-coupled receptors: Roles of G-protein-coupled receptor kinases and beta-arrestin proteins. Prog. Neurobiol. 66:61-79, 2002.
93. Arden, J.R., Segredo, V., Wang, Z., et al. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK293 cells. J. Neurochem. 65:1636-1645, 1995.
94. Li, J.G., Luo, L.Y., Krupnick, J.G., et al. U50,488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation. J. Biol. Chem. 274:12087-12094, 1999.
95. Trapaidze, N., Keith, D.E., Cvejic, S., et al. Sequestration of the delta-opioid receptor. Role of the C terminus in agonist-mediated internalization. J. Biol. Chem. 271:29279-29285, 1996.
96. Sternini, C., Spann, M., Anton, B., et al. Agonist-selective endocytosis of mu-opioid receptor by neurons in vivo. Proc. Natl. Acad. Sci. U.S.A. 93:9241-9246, 1996.
97. Marvizon, J.C., Grady, E.F., Waszak-McGee, J., et al. Internalization of mu-opioid receptors in rat spinal cord slices. Neuroreport 10:2329-2334, 1999.
98. Hackel, P.O., Zwick, E., Prenzel, N., et al. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11:184-189, 1999.
99. Jordan, B.A., and Devi, L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697-700, 1999.
100. Gouldson, P.R., Snell, C.R., Bywater, R.P., et al. Domain swapping in G-protein-coupled receptor dimers. Prot. Eng. 11:1181-1193, 1998.
101. Hebert, T.E., and Bouvier, M. Structural and functional aspects of G-protein-coupled receptor oligomerization. Biochem. Cell Biol. 76:1-11, 1998.
102. Cvejic, S., and Devi, L.A. Dimerization of the delta-opioid receptor: Implication for a role in receptor internalization. J. Biol. Chem. 272:26959-26964, 1997.
103. George, S.R., Fan, T., Xie, Z., et al. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 275:26128-26135, 2000.
104. Jordan, B.A., Trapaidze, N., Gomes, I., et al. Oligomerization of opioid receptors with beta-2-adrenergic receptors: A role in trafficking and mitogen-activated protein kinase activation. Proc. Natl. Acad. Sci. U.S.A. 98:343-348, 2001.
105. He, L., Fong, J., von Zastrow, M., et al. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108:271-282, 2002.
106. Pfeiffer, M., Kirscht, S., Stumm, R., et al. Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization. J. Biol. Chem. 278:51630-51637, 2003.
107. McVey, M., Ramsay, D., Kellett, E., et al. Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human delta-opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy. J. Biol. Chem. 276:14092-14099, 2001.
108. Kato, R., and Foex, P. Fentanyl reduces infarction but not stunning via delta-opioid receptors and protein kinase C in rats. Br. J. Anaesth. 84:608-614, 2000.
109. Corchero, J., Manzanares, J., and Fuentes, J.A. Cannabinoid/opioid crosstalk in the central nervous system. Crit. Rev. Neurobiol. 16:159-172, 2004.
110. Tegeder, I., and Geisslinger, G. Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications. Pharmacol. Rev. 56:351-369, 2004.
111. Bodnar, R.J., and Klein, G.E. Endogenous opiates and behavior: 2003. Peptides 25:2205-2256, 2004.
112. Malinowski, K., Shock, E.J., Rochelle, P., et al. Plasma beta-endorphin, cortisol, and immune responses to acute exercise are altered by age and exercise training in horses. Equine Vet. J. Suppl. 267-273, 2006.
113. Stanojevic, S., Mitic, K., Vujic, V., et al. Beta-endorphin differentially affects inflammation in two inbred rat strains. Eur. J. Pharmacol. 549:157-165, 2006.
114. Cui, Y., Lee, T.F., and Wang, L.C. State-dependent changes of brain endogenous opioids in mammalian hibernation. Brain Res. Bull. 40:129-133, 1996.
115. Tamura, Y., Monden, M., Shintani, M., et al. Neuroprotective effects of hibernation-regulating substances against low-temperature-induced cell death in cultured hamster hippocampal neurons. Brain Res. 1108:107-116, 2006.
116. Lapalu, S., Moisand, C., Mazarguil, H., et al. Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides. FEBS Lett. 417:333-336, 1997.
117. Lapalu, S., Moisand, C., Butour, J.L., et al. Different domains of the ORL1 and kappa-opioid receptors are involved in recognition of nociceptin and dynorphin A. FEBS Lett. 427:296-300, 1998.
118. Lang, R.E., Hermann, K., Dietz, R., et al. Evidence for the presence of enkephalins in the heart. Life Sci. 32:399-406, 1983.
119. Caffrey, J.L., Boluyt, M.O., Younes, A., et al. Aging, cardiac proenkephalin mRNA, and enkephalin peptides in the Fisher 344 rat. J. Mol. Cell Cardiol. 26:701-711, 1994.
120. Yang, H.Y., Hexum, T., and Costa, E. Opioid peptides in adrenal gland. Life Sci. 27:1119-1125, 1980.
121. Fleminger, G., Howells, R.D., Kilpatrick, D.L., et al. Intact proenkephalin is the major enkephalin-containing peptide produced in rat adrenal glands after denervation. Proc. Natl. Acad. Sci. U.S.A. 81:7985-7988, 1984.
122. Noble, F., and Roques, B.P. Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs. Exp. Opin. Ther. Targ. 11:145-159, 2007.
123. Stefano, G.B., Goumon, Y., Casares, F., et al. Endogenous morphine. Trends Neurosci. 23:436-442, 2000.
124. Akil, H., Watson, S.J., Young, E., et al. Endogenous opioids: Biology and function. Ann. Rev. Neurosci. 7:223-255, 1984.
125. Holaday, J.W. Cardiovascular effects of endogenous opiate systems. Ann. Rev. Pharmacol. Toxicol. 23:541-594, 1983.
126. Scarone, S., Gambini, O., Calabrese, G., et al. Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: Preliminary data. Psychiatry Res. 32:159-166, 1990.
127. Barron, B.A., Jones, C.E., and Caffrey, J.L. Pericardial repair depresses canine cardiac catecholamines and met-enkephalin. Regul. Pept. 59:313-320, 1995.
128. Zhao, P., Huang, Y., and Zuo, Z. Opioid preconditioning induces opioid receptor-dependent delayed neuroprotection against ischemia in rats. J. Neuropathol. Exp. Neurol. 65:945-952, 2006.
129. Gross, E.R., Hsu, A.K., and Gross, G.J. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am. J. Physiol. Heart Circ. Physiol. 291:H827-H834, 2006.
130. Przewlocka, B., Lason, W., and Przewlocki, R. Time-dependent changes in the activity of opioid systems in the spinal cord of monoarthritic rats - a release and in situ hybridization study. Neuroscience 46:209-216, 1992.
131. Mousa, S.A., Zhang, Q., Sitte, N., et al. beta-endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue. J. Neuroimmunol. 115:71-78, 2001.
132. Stein, C., Hassan, A.H., Przewlocki, R., et al. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc. Natl. Acad. Sci. U.S.A. 87:5935-5939, 1990.
133. Machelska, H., Mousa, S.A., Brack, A., et al. Opioid control of inflammatory pain regulated by intercellular adhesion molecule-1. J. Neurosci. 22:5588-5596, 2002.
134. Peterson, P.K., Gekker, G., Hu, S., et al. Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: Implication of an atypical mu-opioid receptor. Neuropharmacology 38:273-278, 1999.
135. Sundar, K.S., Kamaraju, L.S., Dingfelder, J., et al. beta-endorphin enhances the replication of neurotropic human immunodeficiency virus in fetal perivascular microglia. J. Neuroimmunol. 61:97-104, 1995.
136. Chao, C.C., Gekker, G., Sheng, W.S., et al. Endogenous opioid peptides suppress cytokine-mediated upregulation of HIV-1 expression in the chronically infected promonocyte clone U1. Adv. Exp. Med. Biol. 373:65-72, 1995.
137. Azuma, Y., and Ohura, K. Endomorphins 1 and 2 inhibit IL-10 and IL-12 production and innate immune functions, and potentiate NF-kappaB DNA binding in THP-1 differentiated to macrophage-like cells. Scand. J. Immunol. 56:260-269, 2002.
138. Neudeck, B.L., and Loeb, J.M. Endomorphin-1 alters interleukin-8 secretion in Caco-2 cells via a receptor mediated process. Immunol. Lett. 84:217-221, 2002.
139. Garcia, I., Perez-Castillo, A., Moreno, J., et al. Beta-endorphin inhibits interleukin-2 release and expression of interleukin-2 receptors in concanavalin A-stimulated splenic lymphocytes. Lymphokine Cytokine Res. 11:339-345, 1992.
140. Takeba, Y., Suzuki, N., Kaneko, A., et al. Endorphin and enkephalin ameliorate excessive synovial cell functions in patients with rheumatoid arthritis. J. Rheumatol. 28:2176-2183, 2001.
141. Refojo, D., Kovalovsky, D., Young, J.I., et al. Increased splenocyte proliferative response and cytokine production in beta-endorphin-deficient mice. J. Neuroimmunol. 131:126-134, 2002.
142. Zagon, I.S., Sassani, J.W., Kane, E.R., et al. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor. Brain Res. 759:92-102, 1997.
143. Kishi, H., Mishima, H.K., Sakamoto, I., et al. Stimulation of retinal pigment epithelial cell growth by neuropeptides in vitro. Curr. Eye Res. 15:708-713, 1996.
144. Bender, T., Torok, I., Barna, I., et al. Beta endorphin-like immunoreactivity in human aqueous humor and crystalline lens. Peptides 22:685-687, 2001.
145. Han, J.S. Acupuncture and endorphins. Neurosci. Lett. 361:258-361, 2004.
146. Chu, T.C., and Potter, D.E. Ocular hypotension induced by electroacupuncture. J. Ocul. Pharmacol. Ther. 18:293-305, 2002.
147. Kim, M.S., Seo, K.M., and Nam, TC. Effect of acupuncture on intraocular pressure in normal dogs. J. Vet. Med. 67:1281-1282, 2005.
148. Kurusu, M., Watanabe, K., Nakazawa, T., et al. Acupuncture for patients with glaucoma. Explore 1:372-376, 2005.
149. Karabatakis, V.E., Natsis, K.I., Chatzibalis, T.E., et al. Correlating intraocular pressure, blood pressure, and heart rate changes after jogging. Eur. J. Ophthalmol. 14:117-122, 2004.
150. Dane, S., Kocer, I., Demirel, H., et al. Effect of acute submaximal exercise on intraocular pressure in athletes and sedentary subjects. Int. J. Neurosci. 116:1223-1230, 2006.
151. Bender, T., Nagy, G., Barna, I., et al. The effect of physical therapy on beta-endorphin levels. Eur. J. Appl. Physiol. 100:371-382, 2007.
152. Chan, H.H.L., Leung, M.C.P., and So, K.-F. Electroacupuncture provides a new approach to neuroprotection in rats with induced glaucoma. J. Alt. Comp. Med. 11:315-322, 2005.
153. Martin-Kleiner, I., Balog, T., and Gabrilovac, J. Signal transduction induced by opioids in immune cells: A review. Neuroimmunomodulation 13:1-7, 2006.
154. Garzon, J., Juarros, J.L., Castro, M.A., et al. Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain. Mol. Pharmacol. 47:738-744, 1995.
155. De Lean, A., Stadel, J.M., and Lefkowitz, R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 255:7108-7117, 1980.
156. Gilman, A.G. G-proteins: Transducers of receptor-generated signals. Ann. Rev. Biochem. 56:615-649, 1987.
157. Garzon, J., Garcia-Espana, A., and Sanchez-Blazquez, P. Opioids binding mu and delta receptors exhibit diverse efficacy in the activation of Gi2 and G(x/z) transducer proteins in mouse periaqueductal gray matter. J. Pharmacol. Exp. Ther. 281:549-557, 1997.
158. Garzon, J., Castro, M., and Sanchez-Blazquez, P. Influence of Gz and Gi2 transducer proteins in the affinity of opioid agonists to mu receptors. Eur. J. Neurosci. 10:2557-2564, 1998.
159. Sanchez-Blazquez, P., Gomez-Serranillos, P., and Garzon, J. Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res. Bull. 54:229-235, 2001.
160. Sanchez-Blazquez, P., Garcia-Espana, A., and Garzon, J. In vivo injection of antisense oligodeoxynucleotides to G-alpha subunits and supraspinal analgesia evoked by mu- and delta-opioid agonists. J. Pharmacol. Exp. Ther. 275:1590-1596, 1995.
161. Standifer, K.M., Rossi, G.C., and Pasternak, G.W. Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G-protein alpha subunits. Mol. Pharmacol. 50:293-298, 1996.
162. Garzon, J., Martinez-Pena, Y., and Sanchez-Blazquez, P. Gx/z is regulated by mu- but not deltaopioid receptors in the stimulation of the low Km GTPase activity in mouse periaqueductal grey matter. Eur. J. Neurosci. 9:1194-1200, 1997.
163. Ho, M.K., and Wong, Y.H. G(z) signaling: Emerging divergence from G(i) signaling. Oncogene 20:1615-1625, 2001.
164. Ho, M.K., Yung, L.Y., Chan, J.S., et al. Galpha(14) links a variety of G(i)- and G(s)-coupled receptors to the stimulation of phospholipase C. Br. J. Pharmacol. 132:1431-1440, 2001.
165. Lee, J.W., Joshi, S., Chan, J.S., et al. Differential coupling of mu-, delta-, and kappa-opioid receptors to G-alpha-16-mediated stimulation of phospholipase C. J. Neurochem. 70:2203-2211, 1998.
166. Liu, A.M., and Wong, Y.H. Mu-opioid receptor-mediated phosphorylation of IkappaB kinase in human neuroblastoma SH-SY5Y cells. Neurosignals 14:136-142, 2005.
167. Russell, K.R., and Potter, D.E. Biphasic alterations of cAMP levels and inhibition of norepinephrine release in iris-ciliary body by bremazocine. J. Pharmacol. Exp. Ther. 298:941-946, 2001.
168. Wax, M.B. Signal transduction in the ciliary epithelium. In: S. Drance, M., VanBuskirk, and Neufeld, A., eds. Pharmacology of Glaucoma. Baltimore: Williams & Wilkins, 1992:184-210.
169. Korenfeld, M.S., and Becker, B. Atrial natriuretic peptides. Effects on intraocular pressure, cGMP, and aqueous flow. Invest. Ophthalmol. Vis. Sci. 30:2385-2392, 1989.
170. Dortch-Carnes, J., and Potter, D.E. Inhibition of cAMP accumulation by kappa-receptor activation in isolated iris-ciliary bodies: Role of phosphodiesterase and protein kinase C. J. Pharmacol. Exp. Ther. 301:599-604, 2002.
171. Sharma, S.K., Klee, W.A., and Nirenberg, M. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc. Natl. Acad. Sci. U.S.A. 72:3092-3096, 1975.
172. Frey, E.A., and Kebabian, J.W. A mu-opiate receptor in 7315c tumor tissue mediates inhibition of immunoreactive prolactin release and adenylate cyclase activity. Endocrinology 115:1797-1804, 1984.
173. Avidor-Reiss, T., Nevo, I., Saya, D., et al. Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J. Biol. Chem. 272:5040-5047, 1997.
174. Chan, J.S., Chiu, T.T., and Wong, Y.H. Activation of type II adenylyl cyclase by the cloned mu-opioid receptor: Coupling to multiple G-proteins. J. Neurochem. 65:2682-2689, 1995.
175. North, R.A., Williams, J.T., Surprenant, A., et al. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc. Natl. Acad. Sci. U.S.A. 84:5487-5491, 1987.
176. Surprenant, A., Shen, K.Z., North, R.A., et al. Inhibition of calcium currents by noradrenaline, somatostatin, and opioids in guinea-pig submucosal neurones. J. Physiol. 431:585-608, 1990.
177. Mulder, A.H., Wardeh, G., Hogenboom, F., et al. Kappa- and delta-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release. Nature 308:278-280, 1984.
178. Schoffelmeer, A.N., Rice, K.C., Jacobson, A.E., et al. Mu-, delta-, and kappa-opioid receptor-mediated inhibition of neurotransmitter release and adenylate cyclase activity in rat brain slices: Studies with fentanyl isothiocyanate. Eur. J. Pharmacol. 154:169-178, 1988.
179. Russell, K.R., Moore, T.T., and Potter, D.E. Elevation of atrial natriuretic peptide levels in aqueous humor of the rabbit by kappa opioid receptor agonists. Neuropeptides 35:232-237, 2001.
180. 3H]thymidine incorporation into DNA: Evidence for the involvement of pertussis toxin-sensitive G-protein-coupled phosphoinositide turnover. J. Neurochem. 60:1505-1511, 1993.
181. 2+ system through cross-talk between opioid receptors and P2-purinergic or bradykinin receptors in NG 108-15 cells. A permissive role for pertussis toxin-sensitive G-proteins. Biochem. J. 290(Pt. 1):241-247, 1993.
182. Chen, L., and Huang, L.Y. Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a mu-opioid. Neuron 7:319-326, 1991.
183. Jin, W., Lee, N.M., Loh, H.H., et al. Dual excitatory and inhibitory effects of opioids on intracellular calcium in neuroblastoma x glioma hybrid NG108-15 cells. Mol. Pharmacol. 42:1083-1089, 1992.
184. Smart, D., Smith, G., and Lambert, D.G. mu-opioid receptor stimulation of inositol (1,4,5)trisphosphate formation via a pertussis toxin-sensitive G-protein. J. Neurochem. 62:1009-1014, 1994.
185. Baxter, G.F., Goma, F.M., and Yellon, D.M. Involvement of protein kinase C in the delayed cytoprotection following sublethal ischaemia in rabbit myocardium. Br. J. Pharmacol. 115:222-224, 1995.
186. Lawlor, M.A., and Alessi, D.R. PKB/Akt: A key mediator of cell proliferation, survival, and insulin responses? J. Cell. Sci. 114(Pt. 16):2903-2910, 2001.
187. Dudek, H., Datta, S.R., Franke, T.F., et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275:661-665, 1997.
188. Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell. Biol. 10:262-267, 1998.
189. Yao, R., and Cooper, G.M. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267:2003-2006, 1995.
190. Iglesias, M., Segura, M.F., Comella, J.X., et al. mu-opioid receptor activation prevents apoptosis following serum withdrawal in differentiated SH-SY5Y cells and cortical neurons via phosphatidylinositol 3-kinase. Neuropharmacology 44:482-492, 2003.
191. Kim, M.S., Cheong, Y.P., So, H.S., et al. Protective effects of morphine in peroxynitrite-induced apoptosis of primary rat neonatal astrocytes: Potential involvement of G-protein and phosphatidylinositol 3-kinase (PI3 kinase). Biochem. Pharmacol. 61:779-786, 2001.
192. Downward, J. How BAD phosphorylation is good for survival. Nat. Cell. Biol. 1:E33-E35, 1999.
193. Pagliaro, P. Differential biological effects of products of nitric oxide (NO) synthase: It is not enough to say NO. Life Sci. 73:2137-2149, 2003.
194. Dortch-Carnes, J., and Russell, K. Morphine-stimulated nitric oxide release in rabbit aqueous humor. Exp. Eye Res. 84:185-190, 2007.
195. Bonfiglio, V., Bucolo, C., Camillieri, G., et al. Possible involvement of nitric oxide in morphine-induced miosis and reduction of intraocular pressure in rabbits. Eur. J. Pharmacol. 534:227-232, 2006.
196. Gabrilovac, J., Balog, T., and Andreis, A. Dynorphin-A(1-17) decreases nitric oxide release and cytotoxicity induced with lipopolysaccharide plus interferon-gamma in murine macrophage cell line J774. Biomed. Pharmacother. 57:351-358, 2003.
197. Marshall, C.J. MAP kinase kinase kinase, MAP kinase kinase, and MAP kinase. Curr. Opin. Genet. Dev. 4:82-89, 1994.
198. Robinson, M.J., and Cobb, M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell. Biol. 9:180-186, 1997.
199. Roux, P.P., and Blenis, J. ERK- and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 68:320-344, 2004.
200. Karin, M. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann. N.Y. Acad. Sci. 851:139-146, 1998.
201. Obata, T., Brown, G.E., and Yaffe, M.B. MAP kinase pathways activated by stress: The p38 MAPK pathway. Crit. Care Med. 28(Suppl.):N67-N77, 2000.
202. Tso, P.H., Yung, L.Y., and Wong, Y.H. Regulation of adenylyl cyclase, ERK1/2, and CREB by Gz following acute and chronic activation of the delta-opioid receptor. J. Neurochem. 74:1685-1693, 2000.
203. Belcheva, M.M., Clark, A.L., Haas, P.D., et al. Muand kappa-opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J. Biol. Chem. 280:27662-27669, 2005.
204. Maulik, N., Yoshida, T., Zu, Y.L., et al. Ischemic preconditioning triggers tyrosine kinase signaling: A potential role for MAPKAP kinase 2. Am. J. Physiol. 275(Pt 2.):H1857-H1864, 1998.
205. Strohm, C., Barancik, T., Bruhl, M.L., et al. Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium. J. Cardiovasc. Pharmacol. 36:218-229, 2000.
206. Fryer, R.M., Hsu, A.K., and Gross, G.J. ERK and p38 MAP kinase activation are components of opioid-induced delayed cardioprotection. Basic Res. Cardiol. 96:136-142, 2001.
207. Carroll, R., and Yellon, D.M. Delayed cardioprotection in a human cardiomyocyte-derived cell line: The role of adenosine, p38MAP kinase, and mitochondrial KATP. Basic Res. Cardiol. 95:243-249, 2000.
208. Yue, T.L., Wang, C., Gu, J.L., et al. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ. Res. 86:692-699, 2000.
209. Meriney, S.D., Gray, D.B., and Pilar, G. Morphine-induced delay of normal cell death in the avian ciliary ganglion. Science 228:1451-1453, 1985.
210. Gupta, K., Kshirsagar, S., Chang, L., et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 62:4491-4498, 2002.
211. Singhal, P.C., Sharma, P., Sanwal, V., et al. Morphine modulates proliferation of kidney fibroblasts. Kidney Int. 53:350-357, 1998.
212. Persson, A.I., Thorlin, T., Bull, C., et al. Opioid-induced proliferation through the MAPK pathway in cultures of adult hippocampal progenitors. Mol. Cell. Neurosci. 23:360-372, 2003.
213. Moon, T.D. The effect of opiates upon prostatic carcinoma cell growth. Biochem. Biophys. Res. Commun. 153:722-727, 1988.
214. Ni, X., Lin, B.C., Song, C.Y., et al. Dynorphin A enhances mitogen-induced proliferative response and interleukin-2 production of rat splenocytes. Neuropeptides 33:137-143, 1999.
215. Law, P.Y., and Bergsbaken, C. Properties of delta-opioid receptor in neuroblastoma NS20Y: Receptor activation and neuroblastoma proliferation. J. Pharmacol. Exp. Ther. 272:322-332, 1995.
216. Meriney, S.D., Ford, M.J., Oliva, D., et al. Endogenous opioids modulate neuronal survival in the developing avian ciliary ganglion. J. Neurosci. 11:3705-3717, 1991.
217. Sakaguchi, M., Fujimori, T., Satoh, T., et al. Effects of opioids on neuronal survival in culture of embryonic chick dorsal root ganglion neurons. Neurosci. Lett. 262:17-20, 1999.
218. Dermitzaki, E., Chatzaki, E., Gravanis, A., et al. Opioids transiently prevent activation of apoptotic mechanisms following short periods of serum withdrawal. J. Neurochem. 74:960-969, 2000.
219. Williams, J.T., Christie, M.J., and Manzoni, O. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 81:299-343, 2001.
220. Tencheva, Z.S., Belcheva, M.M., Velichkova, A.A., et al. Opioid regulation of AP-1 DNA-binding activity in NG108-15 cells under conditions of opioid-receptor adaptation. Brain Res. Mol. Brain Res. 48:156-158, 1997.
221. Hou, Y.N., Vlaskovska, M., Cebers, G., et al. A mu-receptor opioid agonist induces AP-1 and NF-kappa B transcription factor activity in primary cultures of rat cortical neurons. Neurosci. Lett. 212:159-162, 1996.
222. Riksen, N.P., Smits, P., and Rongen, G.A. Ischemic preconditioning: From molecular characterization to clinical application - part I. Neth. J. Med. 62:353-363, 2004.
223. Tateyama, S., Ikeda, T., Kosai, K., et al. Endomorphins suppress nociception-induced c-Fos and Zif/268 expression in the rat spinal dorsal horn. Eur. J. Pharmacol. 451:79-87, 2002.
224. Roy, S., Chapin, R.B., Cain, K.J., et al. Morphine inhibits transcriptional activation of IL-2 in mouse thymocytes. Cell. Immunol. 179:1-9, 1997.
225. Roy, S., Cain, K.J., Chapin, R.B., et al. Morphine modulates NF kappa B activation in macrophages. Biochem. Biophys. Res. Commun. 245:392-396, 1998.
226. Peyman, G.A., Rahimy, M.H., and Fernandes, M.L. Effects of morphine on corneal sensitivity and epithelial wound healing: Implications for topical ophthalmic analgesia. Br. J. Ophthalmol. 78:138-141, 1994.
227. Frey, W.H., Nelson, J.D., Frick, M.L., et al. Prolactin immunoreactivity in human tears and lacrimal glands: Possible implications for tear production. In: F.J. Holly, ed. The Preocular Tear Film in Health, Disease and Contact Lens Wear. Lubbock, TX: Dry Eye Institute, 1986:798-807.
228. Lehtosalo, J., Uusitalo, H., Mahrberg, T., et al. Nerve fibers showing immunoreactivities for proenkephalin A-derived peptides in the lacrimal glands of the guinea pig. Graefe's Arch. Clin. Exp. Ophthalmol. 227:455-458, 1989.
229. Cripps, M.M., and Bennett, D.J. Proenkephalin A derivatives in lacrimal gland: Occurrence and regulation of lacrimal function. Exp. Eye Res. 54:829-834, 1992.
230. Meneray, M.A., Fields, T.Y., and Bennett, D.J. Gi2 and Gi3 couple met-enkephalin to inhibition of lacrimal secretion. Invest. Ophthalmol. Vis. Sci. 39:1339-1345, 1998.
231. Murray, R.B., Adler, M.W., and Korczyn, A.D. The pupillary effects of opioids. Life Sci. 33:495-509, 1983.
232. Bjorklund, H., Hoffer, B., Olson, L., et al. Enkephalin immunoreactivity in iris nerves: Distribution in normal and grafted irides, persistence, and enhanced fluorescence after denervations. Histochemistry 80:1-7, 1984.
233. Lee, H.K., and Wang, S.C. Mechanism of morphine-induced miosis in the dog. J. Pharmacol. Exp. Ther. 192:415-431, 1975.
234. Wang, Y.X., Clarke, G.D., Sbacchi, M., et al. Contribution of alpha-2 adrenoceptors to kappa opioid agonist-induced water diuresis in the rat. J. Pharmacol. Exp. Ther. 270:244-249, 1994.
235. Salas, S.P., Roblero, J., Ureta, H., et al. Diuretic effect of bremazocine, a kappa-opioid with central and peripheral sites of action. J. Pharmacol. Exp. Ther. 250:992-999, 1989.
236. Salas, S.P., Roblero, J.S., Lopez, L.F., et al. [N-methyl-Tyr1,N-methyl- Arg7-D-Leu8]-dynorphin-A-(1-8)-ethylamide, a stable dynorphin analog, produces diuresis by kappa-opiate receptor activation in the rat. J. Pharmacol. Exp. Ther. 262:979-986, 1992.
237. Zhai, Q.Z., and Ingenito, A.J. Sustained antihypertensive effects of chronic administration of two kappa-opioid agonists in spontaneously hypertensive rats. Am. J. Ther. 4:173-180, 1997.
238. Zhai, Q.Z., and Ingenito, A.J. Comparative hypotensive actions of three nonpeptide kappa-opioid agonists on hippocampus of SHRs and normotensive WKY rats. J. Cardiovasc. Pharmacol. 31:806-812, 1998.
239. Nagao, S., Bemana, I., Kuratani, H., et al. Niravoline, a selective kappa-opioid receptor agonist effectively reduces elevated intracranial pressure. Exp. Brain Res. 130:338-344, 2000.
240. Uusitalo, R. The action of physostigmine, morphine, cyclopentolate, and homatropine on the secretion and outflow of aqueous humour in the rabbit eye. Acta. Physiol. Scand. 86:239-249, 1972.
241. Fimiani, C., Arcuri, E., Santoni, A., et al. Mu3 opiate receptor expression in lung and lung carcinoma: Ligand binding and coupling to nitric oxide release. Cancer Lett. 146:45-51, 1999.
242. Potter, D.E., Russell, K.R., and Manhiani, M. Bremazocine increases C-type natriuretic peptide levels in aqueous humor and enhances outflow facility. J. Pharmacol. Exp. Ther. 309:548-553, 2004.
243. Trendelenburg, U. The action of morphine on the superior cervical ganglion and on the nictitating membrane of the cat. Br. J. Pharmacol. Chemother. 12:79-85, 1957.
244. Dubocovich, M.L., and Langer, S.Z. Pharmacological differentiation of presynaptic inhibitory alpha-adrenoceptors and opiate receptors in the cat nictitating membrane. Br. J. Pharmacol. 70:383-393, 1980.
245. Slaughter, M.M., Mattler, J.A., and Gottlieb, D.I. Opiate binding sites in the chick, rabbit, and goldfish retina. Brain Res. 339:39-47, 1985.
246. Howells, R.D., Groth, J., Hiller, J.M., et al. Opiate binding sites in the retina: Properties and distribution. J. Pharmacol. Exp. Ther. 215:60-64, 1980.
247. Ulrich, W.D., and Reimann, J. Survival and revival times of the retina: ERG studies at total ocular ischemia in rabbits and cats. Doc. Ophthalmol. 63:91-99, 1986.
248. Tsujikawa, A., Ogura, Y., Hiroshiba, N., et al. Retinal ischemia-reperfusion injury attenuated by blocking of adhesion molecules of vascular endothelium. Invest. Ophthalmol. Vis. Sci. 40:1183-1190, 1999.
249. Lu, N., Shimura, M., Kinukawa, Y., et al. Quantitative analysis of leukocyte dynamics in retinal microcirculation of rats with short-term ischemia-reperfusion injury. Curr. Eye Res. 19:403-410, 1999.
250. Roth, S. Endogenous neuroprotection in the retina. Brain Res. Bull. 62:461-466, 2004.
251. Whitlock, N.A., Agarwal, N., Ma, J.X., et al. Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. Invest. Ophthalmol. Vis. Sci. 46:1092-1098, 2005.
252. 2+-induced cell death in a caspase-dependent and -independent manner in rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 46:1085-1091, 2005.
253. Kuroiwa, S., Katai, N., and Yoshimura, N. A possible role for p16INK4 in neuronal cell death after retinal ischemia-reperfusion injury. Invest. Ophthalmol. Vis. Sci. 40:528-533, 1999.
254. Katai, N., and Yoshimura, N. Apoptotic retinal neuronal death by ischemia-reperfusion is executed by two distinct caspase family proteases. Invest. Ophthalmol. Vis. Sci. 40:2697-2705, 1999.
255. Ettaiche, M., Fillacier, K., Widmann, C., et al. Riluzole improves functional recovery after ischemia in the rat retina. Invest. Ophthalmol. Vis. Sci. 40:729-736, 1999.
256. Szabo, M.E., Droy-Lefaix, M.T., Doly, M., et al. Ischemia and reperfusion-induced histologic changes in the rat retina. Demonstration of a free radical-mediated mechanism. Invest. Ophthalmol. Vis. Sci. 32:1471-1478, 1991.
257. Sugawara, T., and Chan, P.H. Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. Antiox. Redox. Signal. 5:597-607, 2003.
258. Hildeman, D.A. Regulation of T-cell apoptosis by reactive oxygen species. Free Radic. Biol. Med. 36:1496-1504, 2004.
259. Tezel, G. Oxidative stress in glaucomatous degeneration: Mechanisms and consequences. Prog. Ret. Eye Res. 25:490-513, 2006.
260. Murry, C.E., Jennings, R.B., and Reimer, K.A. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136, 1986.
261. Schultz, J.E., and Gross, G.J. Opioids and cardioprotection. Pharmacol. Ther. 89:123-137, 2001.
262. Kume, M., Yamamoto, Y., Saad, S., et al. Ischemic preconditioning of the liver in rats: Implications of heat-shock protein induction to increase tolerance of ischemia-reperfusion injury. J. Lab. Clin. Med. 128:251-258, 1996.
263. Neely, C.F., and Keith, I.M. A1 adenosine receptor antagonists block ischemia-reperfusion injury of the lung. Am. J. Physiol. 268(Pt. 1):L1036-L1046, 1995.
264. Kato, H., Araki, T., Murase, K., et al. Induction of tolerance to ischemia: Alterations in second-messenger systems in the gerbil hippocampus. Brain Res. Bull. 29:559-565, 1992.
265. Gidday, J.M., Fitzgibbons, J.C., Shah, A.R., et al. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat. Neurosci. Lett. 168:221-224, 1994.
266. Roth, S., Li, B., Rosenbaum, P.S., et al. Preconditioning provides complete protection against retinal ischemic injury in rats. Invest. Ophthalmol. Vis. Sci. 39:777-785, 1998.
267. Qiu, Y., Rizvi, A., Tang, X.L., et al. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. Am. J. Physiol. 273(Pt 2):H2931-H2936, 1997.
268. Centurion, S.A., Centurion, L.M., Souza, M.E., et al. Effects of ischemic liver preconditioning on hepatic ischemia/reperfusion injury in the rat. Transpl. Proc. 39:361-364, 2007.
269. Clavien, P.A., Yadav, S., Sindram, D., et al. Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. Ann. Surg. 232:155-162, 2000.
270. Nandagopal, K., Dawson, T.M., and Dawson, V.L. Critical role for nitric oxide signaling in cardiac and neuronal ischemic preconditioning and tolerance. J. Pharmacol. Exp. Ther. 297:474-478, 2001.
271. Martin, H.B., and Walter, C.L. Preconditioning: An endogenous defense against the insult of myocardial ischemia. Anesth. Analg. 83:639-645, 1996.
272. Roth, S., Dreixler, J.C., Shaikh, A.R., et al. Mitochondrial potassium ATP channels and retinal ischemic preconditioning. Invest. Ophthalmol. Vis. Sci. 47:2114-2124, 2006.
273. Zhao, Z.Q., and Vinten-Johansen, J. Postconditioning: Reduction of reperfusion-induced injury. Cardiovasc. Res. 70:200-211, 2006.
274. Dortch-Carnes, J., and Potter, D.E. Effect of bremazocine, a kappa-opioid receptor agonist, on inositol phosphate formation in isolated iris-ciliary bodies. Pharmacology 66:100-106, 2002.
275. Chen, J., and Simon, R. Ischemic tolerance in the brain. Neurology 48:306-311, 1997.
276. Piot, C.A., Padmanaban, D., Ursell, P.C., et al. Ischemic preconditioning decreases apoptosis in rat hearts in vivo. Circulation 96:1598-1604, 1997.
277. Shimizu, S., Nagayama, T., Jin, K.L., et al. bcl-2 antisense treatment prevents induction of tolerance to focal ischemia in the rat brain. J. Cereb. Blood Flow Metab. 21:233-243, 2001.
278. Caprioli, J., Kitano, S., and Morgan, J.E. Hyperthermia and hypoxia increase tolerance of retinal ganglion cells to anoxia and excitotoxicity. Invest. Ophthalmol. Vis. Sci. 37:2376-2381, 1996.
279. Kin, H., Zatta, A.J., Jiang, R., et al. Activation of opioid receptors mediates the infarct reduction by postconditioning. J. Mol. Cell. Cardiol. 38:827-832, 2005.
280. Zhang, J., Haddad, G.G., and Xia, Y. delta-, but not mu- and kappa-, opioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury. Brain Res. 885:143-153, 2000.
281. Zhang, J., Gibney, G.T., Zhao, P., et al. Neuroprotective role of delta-opioid receptors in cortical neurons. Am. J. Physiol. Cell. Physiol. 282:C1225-C1234, 2002.
282. Lin, X., Xue, X.Y., Wang, R., et al. Protective effects of endomorphins, endogenous opioid peptides in the brain, on human low density lipoprotein oxidation. FEBS J. 273:1275-1284, 2006.
283. Liang, B.T., and Gross, G.J. Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels. Circ. Res. 84:1396-1400, 1999.
284. Kodani, E., Xuan, Y.T., Shinmura, K., et al. Delta-opioid receptor-induced late preconditioning is mediated by cyclo-oxygenase-2 in conscious rabbits. Am. J. Physiol. Heart Circ. Physiol. 283:H1943-H1957, 2002.
285. Wu, S., Li, H.Y., and Wong, T.M. Cardioprotection of preconditioning by metabolic inhibition in the rat ventricular myocyte. Involvement of kappa-opioid receptor. Circ. Res. 84:1388-1395, 1999.
286. Gross, G.J. Role of opioids in acute and delayed preconditioning. J. Mol. Cell. Cardiol. 35:709-718, 2003.
287. Gross, E.R., Hsu, A.K., and Gross, G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ. Res. 94:960-966, 2004.
288. Wang, Y., Xie, W.-Y., He, Y., et al. Role of CDK% in neuroprotection from serum deprivation by mu-opioid receptor agonist. Exp. Neurol. 202:313-323, 2006.